title: [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
authors.forename: Magnus
authors.initials: M
authors.lastname: Dalén
authors.forename: Paul
authors.initials: P
authors.lastname: Hjemdahl
authors.forename: Margareta
authors.initials: M
authors.lastname: Holmström
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Ivert
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D000931:Antidotes / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D019091:Critical Pathways; D000069604:Dabigatran; D016903:Drug Monitoring; D017558:Elective Surgical Procedures; D006470:Hemorrhage / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D012307:Risk Factors; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics
chemical_list: D000925:Anticoagulants; D000931:Antidotes; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran